Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.59 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110539 | 0.89 | NTRK1 (0.56) | NTRK1JMJD6 | |
| SCHEMBL17110544 | 0.88 | NTRK1 (0.57) | NTRK1JMJD6 | |
| SCHEMBL21818874 | 0.84 | LMNA (0.54) | NTRK1JMJD6 | |
| SCHEMBL29633248 | 0.80 | NTRK1 (0.62) | NTRK1NTRK3 | |
| SCHEMBL17110550 | 0.80 | NTRK1 (0.62) | NTRK1NTRK3 | |
| SCHEMBL17111462 | 0.76 | NTRK1 (1.00) | NTRK1NTRK3 | |
| SCHEMBL21942059 | 0.74 | SYK (0.56) | NTRK1SYK | |
| SCHEMBL3367612 | 0.72 | RXRA (0.54) | SYK | |
| SCHEMBL2590647 | 0.71 | RAB9A (0.49) | SYK | |
| SCHEMBL14213194 | 0.71 | RXRA (0.49) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122344-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3122344-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3122345-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3122345-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3122346-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3122346-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10556900-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556900-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180105518-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105518-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | US | disclosed |
| WO-2015148350-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148350-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148344-A2 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148354-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148344-A2 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148373-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148373-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148354-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015143653-A1 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015143654-A1 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105518-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NTRK2, NGF | NTRK1 5/4885JMJD6 2073/4885NTRK3 7/4885 |
| US-10556900-B2 | TrkA kinase inhibitors, compositions and methods thereof | NGFR, NTRK2, NGF | NTRK1 5/4885JMJD6 2073/4885NTRK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.